FinVector is a world leader in R&D and cGMP manufacturing of Viral-Based Gene Therapy products. Our state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an excellent reputation in the gene therapy market. We are authorised under EMA for the production of gene therapy products for clinical and commercial supply.
FinVector’s track record of delivering a tailored service to meet and exceed our clients’ needs goes back two decades, since Professor Seppo Ylä-Herttuala formed the company back in 1993. Today, FinVector is part of Ferring Ventures. We know that the job we do represents a competitive advantage for our partners.
Importantly, we use our scientific expertise and industry knowledge gained through the development of our own products to help clients take viral-based products from the pre-clinical phase, through clinical trials and to the market.
FinVector offers services across a wide range of viral-based product types utilising supsension/adherent based platforms. From our cutting-edge fully-licensed GMP manufacturing facilities in Finland, we have built an extensive pipeline of gene therapy products and technologies for our clients.
The team at FinVector is passionate about delivering excellence for our clients, and we look forward to working with new and existing partners in the years to come.